Abstract
There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder. Physostigmine tended to improve the Dot test, but not serial verbal learning performance in these patients.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Cholinesterase Inhibitors / therapeutic use*
-
Cognition / drug effects*
-
Double-Blind Method
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Memory, Short-Term / drug effects*
-
Physostigmine / therapeutic use*
-
Schizotypal Personality Disorder / drug therapy*
-
Space Perception / drug effects
-
Visual Perception / drug effects
Substances
-
Cholinesterase Inhibitors
-
Physostigmine